FGL1, a Ligand of lymphocyte-activation gene 3 (LAG3) [30], also known as hepassocin, HRFREP-1, and FREP1 [31–34], is primarily expressed on the surface and within the cytoplasm of lung and breast cancer cells. This evidence concerns the gene LAG3 and breast carcinoma.